Journal
VASCULAR CELL
Volume 2, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/2040-2384-2-19
Keywords
-
Categories
Funding
- uvenile Diabetes Research Foundation
- ADA Lions SightFirst Program
- Ophthalmic Research Institute of Australia (AJJ)
- University of Melbourne (ASJ)
- NHMRC (Australia)
- NIH [EY12231, EY015650, EY019309, P20RR024215]
Ask authors/readers for more resources
Background: Kallistatin, a serpin widely produced throughout the body, has vasodilatory, anti-angiogenic, antioxidant, and anti-inflammatory effects. Effects of diabetes and its vascular complications on serum kallistatin levels are unknown. Methods: Serum kallistatin was quantified by ELISA in a cross-sectional study of 116 Type 1 diabetic patients (including 50 with and 66 without complications) and 29 non-diabetic controls, and related to clinical status and measures of oxidative stress and inflammation. Results: Kallistatin levels (mean(SD)) were increased in diabetic vs. control subjects (12.6(4.2) vs. 10.3(2.8) mu g/ml, p = 0.007), and differed between diabetic patients with complications (13.4(4.9) mu g/ml), complication-free patients (12.1 (3.7) mu g/ml), and controls; ANOVA, p = 0.007. Levels were higher in diabetic patients with complications vs. controls, p = 0.01, but did not differ between complication-free diabetic patients and controls, p > 0.05. On univariate analyses, in diabetes, kallistatin correlated with renal dysfunction (cystatin C, r = 0.28, p = 0.004; urinary albumin/creatinine, r = 0.34, p = 0.001; serum creatinine, r = 0.23, p = 0.01; serum urea, r = 0.33, p = 0.001; GFR, r = -0.25, p = 0.009), total cholesterol ( r = 0.28, p = 0.004); LDL-cholesterol (r = 0.21, p = 0.03); gamma-glutamyltransferase (GGT) (r = 0.27, p = 0.04), and small artery elasticity, r = - 0.23, p = 0.02, but not with HbA1c, other lipids, oxidative stress or inflammation. In diabetes, geometric mean (95% CI) kallistatin levels adjusted for covariates, including renal dysfunction, were higher in those with vs. without hypertension (13.6 (12.3-14.9) vs. 11.8 (10.5-13.0) mu g/ml, p = 0.03). Statistically independent determinants of kallistatin levels in diabetes were age, serum urea, total cholesterol, SAE and GGT, adjusted r(2) = 0.24, p < 0.00001. Conclusions: Serum kallistatin levels are increased in Type 1 diabetic patients with microvascular complications and with hypertension, and correlate with renal and vascular dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available